Skip to main content
Top
Published in: International Journal of Hematology 4/2015

01-04-2015 | Case Report

Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient

Authors: Sachiko Kawashima-Goto, Toshihiko Imamura, Masafumi Seki, Motohiro Kato, Kenichi Yoshida, Atsuya Sugimoto, Daisuke Kaneda, Atsushi Fujiki, Mitsuru Miyachi, Takuya Nakatani, Shinya Osone, Hiroyuki Ishida, Tomohiko Taki, Junko Takita, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Hajime Hosoi

Published in: International Journal of Hematology | Issue 4/2015

Login to get access

Abstract

Investigation of genetic alterations associated with relapse in acute lymphoblastic leukemia (ALL) may help to identify druggable targets for specific therapies. Early T-cell precursor ALL (ETP-ALL) is a subtype of T-ALL with poor prognosis. Although the genetic landscape of ETP-ALL has been determined, genetic alterations related to the relapse of ETP-ALL have not been fully investigated. Here, we report the first patient with relapsed pediatric ETP-ALL to exhibit a homozygous JAK3 activating mutation, V674A, caused by acquired uniparental disomy (UPD). Single nucleotide polymorphism array analysis revealed acquired UPD (aUPD) at the 19p13.3-p12 locus only in leukemic cells at relapse. Sanger sequence of the JAK3 gene, which was located at 19p13.1 and frequently mutated in ETP-ALL, was performed in paired leukemic samples to determine homozygous JAK3 V674A mutation only in relapsed leukemic cells. In contrast, leukemic cells at initial diagnosis harbored hemizygous JAK3 V674A mutation. Further, whole-exome sequencing revealed mutations in 18 genes only in relapsed samples, although none of these was recurrent in T-ALL. These findings suggest that aUPD at 19p13.1 is partly associated with relapse in this patient. Pharmacological inhibition of JAK3 may be therapeutic in such cases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukemia: a subtype of very high-risk acute lymphoblastic leukemia. Lancet Oncol. 2009;10:147–56.CrossRefPubMedCentralPubMed Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukemia: a subtype of very high-risk acute lymphoblastic leukemia. Lancet Oncol. 2009;10:147–56.CrossRefPubMedCentralPubMed
2.
go back to reference Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukemia. Nature. 2012;481:157–63.CrossRefPubMedCentralPubMed Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukemia. Nature. 2012;481:157–63.CrossRefPubMedCentralPubMed
3.
go back to reference Choi YL, Kaneda R, Wada T, Fujiwara S, Soda M, Watanabe H, et al. Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res. 2007;31:203–9.CrossRefPubMed Choi YL, Kaneda R, Wada T, Fujiwara S, Soda M, Watanabe H, et al. Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res. 2007;31:203–9.CrossRefPubMed
4.
go back to reference Suzuki N, Yumura-Yagi K, Yoshida M, Hara J, Nishimura S, Kudoh T, et al. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Associated of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer. 2010;54:71–8.CrossRefPubMed Suzuki N, Yumura-Yagi K, Yoshida M, Hara J, Nishimura S, Kudoh T, et al. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Associated of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer. 2010;54:71–8.CrossRefPubMed
5.
go back to reference Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–9.CrossRefPubMed Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–9.CrossRefPubMed
6.
go back to reference Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39:593–5.CrossRefPubMed Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39:593–5.CrossRefPubMed
7.
go back to reference Witthuhn BA, Silvenoinen O, Miura O, Lai KS, Cwik C, Liu ET, et al. Involvement of the JAK-3 Janus kinase in signaling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 1994;370:153–7.CrossRefPubMed Witthuhn BA, Silvenoinen O, Miura O, Lai KS, Cwik C, Liu ET, et al. Involvement of the JAK-3 Janus kinase in signaling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 1994;370:153–7.CrossRefPubMed
8.
go back to reference Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377:65–8.CrossRefPubMed Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377:65–8.CrossRefPubMed
9.
go back to reference Kalender Atak Z, De Keerskaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One. 2012;7:e38463.CrossRefPubMedCentralPubMed Kalender Atak Z, De Keerskaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One. 2012;7:e38463.CrossRefPubMedCentralPubMed
10.
go back to reference Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2014;53:309–16.CrossRefPubMed Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2014;53:309–16.CrossRefPubMed
11.
go back to reference Raghavan M, Smith LL, Lilllington DM, Chaplin T, Kakkas I, Molloy G, et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood. 2008;112:814–21.CrossRefPubMed Raghavan M, Smith LL, Lilllington DM, Chaplin T, Kakkas I, Molloy G, et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood. 2008;112:814–21.CrossRefPubMed
Metadata
Title
Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient
Authors
Sachiko Kawashima-Goto
Toshihiko Imamura
Masafumi Seki
Motohiro Kato
Kenichi Yoshida
Atsuya Sugimoto
Daisuke Kaneda
Atsushi Fujiki
Mitsuru Miyachi
Takuya Nakatani
Shinya Osone
Hiroyuki Ishida
Tomohiko Taki
Junko Takita
Yuichi Shiraishi
Kenichi Chiba
Hiroko Tanaka
Satoru Miyano
Seishi Ogawa
Hajime Hosoi
Publication date
01-04-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1711-y

Other articles of this Issue 4/2015

International Journal of Hematology 4/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine